Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Kalytera (TSXV:KLY) has released results from a recent trial, showing its drug R-107 provides sustained release of nitric oxide 
  • This is significant, as the R-107 drug is intended to replace nitric oxide gas, which is expensive and needs to be administered by a trained professional
  • The drug’s developer, Salzman Group, performed the study on rodents to monitor how long the drug took to be metabolised into the system
  • Results from the studs showed the R-107 drug entered blood plasma within five to eight minutes of injection
  • Kalytera (KLY) is up 20 per cent and is trading at C$0.03 per share 

Kalytera (TSXV:KLY) has released results from a recent trial, showing its drug R-107 provides sustained release of nitric oxide.

This is significant, as the R-107 drug is intended to replace nitric oxide gas, which is expensive and needs to be administered by a trained professional. 

In comparison, the R-107 drug is a simple intramuscular injection that can be metabolised by the body slowly, releasing the nitric oxide gradually. 

The company is acquiring the drug from the Salzman Group, which has provided Kalytera with the drugs most recent study, performed on rodents. 

The study monitored how long it took for the roents to convert R-107 to R-100, thus beginning to the release of nitric oxide.

Results from the study, conducted by Envigo Labs in the UK, has shown the R-107 drug is entering blood plasma within five to eight minutes of injection.

Following that, the drug is being converted to R-100 within 15 minutes, at which point it attains its peak plasma concentration.

R-100 is then clearing out from the plasma with sustained half-lives, averaging 2.7 hours in male rats and 7.7 hours in female rats.

Once the R-100 is released from the plasma, a large volume of the drug is being absorbed into fat stores, giving the body a store that in turn releases over a significant length of time.

Kalytera has stated that the findings suggest that a single dose of the R-107 in humans could produce sustained plasma levels of the active payload R-100, which would then release nitric oxide into the lung over many hours.

Kalytera (KLY) is up 20 per cent and is trading at C$0.03 per share at 11:45 pm EDT. 

More From The Market Herald

" Lumiera Health (TSXV:NHP) partners with natural health industry leader

Lumiera Health (NHP) has signed an MoU to explore a strategic partnership with one of Quebec’s leaders in the natural health industry.

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.

" Reunion (TSX:REUN) appoints Greg Mayes as President and CEO

Reunion Neuroscience (REUN) (formerly Field Trip Health Ltd.) has appointed Greg Mayes as President and Chief Executive Officer.

" Microbix Biosystems (TSX:MBX) announces NCIB

Microbix Biosystems (MBX) has announced a Normal Course Issuer Bid for the repurchase and cancellation of outstanding common shares.